Sign In
2 Mar 2018 12:00
Horizon Discovery Group plc
Board Change
Cambridge, UK, 2 March 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Group"), a global leader in gene editing and gene modulation technologies, announces that, further to the statement issued on 20 February 2018 in which it was noted that Darrin Disley had decided to step down as CEO, Darrin Disley is no longer a Board Director of the Group as of today's date.
Horizon's Board consists of the following representatives:
Dr Ian Gilham
Executive Chairman
Richard Vellacott
Interim Chief Executive Officer and Chief Financial Officer
Dr Jonathan Milner
Non-Executive Director
Mrs Susan Searle
Non-Executive Director
Dr Susan Galbraith
Non-Executive Director
Dr Vishal Gulati
Non-Executive Director
Grahame Cook
Non-Executive Director
ENDS
For further information from Horizon Discovery Group plc, please contact:
Horizon Discovery Group plc
Richard Vellacott, Interim Chief Executive Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.
Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".
Follow the stocks
